Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …

Tissue localization is a critical determinant of T cell immunity. CD8+ T cells are contact-
dependent killers, which requires them to physically be within the tissue of interest to kill …

Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in a wide
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …

Over the last decade, based on the extensive development of preclinical animal studies and
clinical trials, the efficacy, and mechanisms of immunotherapy have been fully explored …

Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

The programmed cell death protein 1 (PD-1) pathway has received considerable attention
due to its role in eliciting the immune checkpoint response of T cells, resulting in tumor cells …

The tumour microenvironment is the primary location in which tumour cells and the host
immune system interact. Different immune cell subsets are recruited into the tumour …

Tumor immunotherapy is a promising therapeutic strategy for patients with advanced
cancers. T cells are key mediators of antitumor function that specifically recognize and react …

Prostate cancers are considered to be immunologically 'cold'tumors given the very few
patients who respond to checkpoint inhibitor (CPI) therapy. Recently, enrichment of …

DNA methylation inhibitors have become the mainstay for treatment of certain
haematological malignancies. In addition to their abilities to reactivate genes, including …